Last updated: February 19, 2026
This analysis details the scope and claims of Spanish patent ES2861374, alongside its patent landscape. The patent, granted to Laboratorios Farmacéuticos Rovi S.A., concerns novel formulations of low molecular weight heparin (LMWH).
What is the Core Invention of ES2861374?
Patent ES2861374 protects novel formulations of low molecular weight heparin (LMWH) designed to improve their stability and administration. The invention focuses on solid pharmaceutical compositions containing LMWH, along with specific excipients that prevent degradation and facilitate dispensing.
The patent claims cover:
- Solid Pharmaceutical Compositions: These compositions are dry and contain LMWH along with at least one stabilizing agent and at least one disintegrant. The LMWH is present in an amount that is effective for anticoagulant therapy.
- Stabilizing Agents: The patent specifies various stabilizing agents, including disaccharides such as sucrose, trehalose, and lactose. These agents protect the LMWH from degradation.
- Disintegrants: These agents, such as crospovidone or sodium croscarmellose, ensure the rapid dissolution of the solid composition upon contact with a liquid, releasing the LMWH for administration.
- Excipient Ratios: The patent defines specific ratios and ranges for the excipients relative to the LMWH to achieve the desired stability and dissolution profiles.
- Methods of Preparation: The claims also encompass methods for preparing these stable solid LMWH formulations.
- Uses of the Formulations: The patent covers the use of these formulations for preparing medicaments for the prevention and treatment of thromboembolic disorders.
The key innovation lies in overcoming the inherent instability of LMWH in solid form, which is typically administered via injection. This patent aims to provide a more stable, potentially room-temperature storable, solid dosage form, simplifying logistics and potentially enabling alternative administration routes in the future.
What are the Key Claims and Scope of ES2861374?
The claims of ES2861374 define the legal boundaries of the invention. The scope is primarily focused on the specific composition and preparation of stable, solid LMWH formulations.
Key aspects of the claim scope include:
- Claim 1: This independent claim defines the core of the invention as a solid pharmaceutical composition comprising:
- Low molecular weight heparin (LMWH).
- At least one stabilizing agent selected from a group including disaccharides.
- At least one disintegrant selected from a group including crospovidone.
- The composition is free from moisture or has a moisture content of less than 5% by weight.
- Dependent Claims: Numerous dependent claims further refine the scope by specifying:
- Particular types of LMWH (e.g., unfractionated heparin or LMWH derived from unfractionated heparin).
- Specific stabilizing agents (e.g., sucrose, trehalose).
- Specific disintegrants (e.g., crospovidone, sodium croscarmellose).
- Ranges for the molecular weight of LMWH.
- Weight ratios between LMWH, stabilizing agent, and disintegrant.
- Additional excipients like fillers, binders, or lubricants.
- Specific methods of preparation (e.g., lyophilization, spray drying).
- Method of Treatment Claims: The patent also covers the use of these formulations for the preparation of medicaments for treating conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and unstable angina.
The scope is narrower than protecting LMWH itself and focuses specifically on the novel solid formulation technology. It does not broadly cover all LMWH therapies but rather these specific stable solid forms. This specificity is crucial for infringement analysis, as competitors would need to use a formulation that falls within the precise wording of the claims.
What is the Patent Landscape for Stable LMWH Formulations?
The patent landscape for LMWH, and particularly for stable solid formulations, is characterized by established patents covering core LMWH compounds and manufacturing processes, alongside newer applications focusing on formulation advancements.
Key players and patent trends in LMWH:
- Originator Patents: Major LMWH products like enoxaparin (Lovenox® by Sanofi) and dalteparin (Fragmin® by Pfizer/BMS) have had their primary compound and manufacturing patents expire. This has led to a significant generic market.
- Generic Competition: The expiration of key originator patents has opened the door for numerous generic manufacturers to produce LMWH. However, replicating the precise manufacturing process and achieving bioequivalence remains a challenge and a subject of patent litigation.
- Formulation Innovation: As core LMWH patents expire, innovation shifts towards improving drug delivery, stability, and patient convenience. This is where patents like ES2861374 become critical. The development of stable solid forms is a significant area of research aimed at differentiating products from existing injectable formulations.
- New Chemical Entities (NCEs) vs. Reformulations: While some companies are developing novel oral anticoagulants (e.g., Factor Xa inhibitors like rivaroxaban, apixaban), others are focusing on improving existing therapies like LMWH. ES2861374 falls into the latter category, seeking to enhance a well-established therapeutic class.
- Specific Technologies: Patents in this space often cover:
- Lyophilization (Freeze-Drying): A common technique to create stable, solid drug products from liquid solutions.
- Spray Drying: Another method for producing dry powders from solutions or suspensions.
- Encapsulation Technologies: Microencapsulation or nanoencapsulation to protect the drug and control its release.
- Excipient Combinations: Novel combinations of excipients that provide enhanced stability or specific release profiles.
ES2861374's Position in the Landscape:
ES2861374 positions Laboratorios Farmacéuticos Rovi S.A. as an innovator in the stable solid formulation of LMWH. Its patenting activity in this area suggests a strategy to:
- Extend Market Exclusivity: By securing patents on novel formulations, Rovi aims to create new market opportunities or defend existing ones against generic competition, even after the primary LMWH patents have expired.
- Differentiate Products: Offering a stable solid LMWH formulation would provide a distinct advantage over standard injectable forms, potentially reducing cold chain requirements and simplifying administration.
- Build a Proprietary Platform: This patent, along with potential related filings, could represent the development of a proprietary platform technology for stabilizing sensitive biomolecules, which could be applied to other drugs.
The patent landscape for LMWH is mature concerning the active pharmaceutical ingredient (API) itself. However, there remains significant patenting activity around advanced formulations and delivery systems, making ES2861374 relevant to ongoing innovation.
What are the Potential Commercial Implications of ES2861374?
The commercial implications of ES2861374 hinge on the successful development, regulatory approval, and market adoption of the claimed stable solid LMWH formulations.
Key commercial considerations:
- Enhanced Product Shelf-Life and Storage: A primary benefit is the potential for room-temperature storage, eliminating the need for cold chain logistics. This significantly reduces distribution costs and complexity, particularly in regions with challenging infrastructure.
- Improved Patient Convenience: While the patent doesn't explicitly claim oral administration, stable solid forms could potentially pave the way for novel delivery devices or even oral formulations in the future, offering a significant advantage over frequent injections for patients requiring long-term anticoagulation.
- Market Differentiation and Extended Exclusivity: For Laboratorios Farmacéuticos Rovi S.A., this patent offers a pathway to differentiate its LMWH products from generic injectable versions and potentially extend market exclusivity beyond the expiry of the original LMWH patents.
- Licensing Opportunities: The proprietary technology could be attractive for licensing to other pharmaceutical companies looking to develop or market stable LMWH formulations in specific territories or for particular indications.
- Competitive Advantage: Successful commercialization of this technology could provide Rovi with a significant competitive edge in the anticoagulation market, particularly if it addresses unmet patient needs related to storage and administration.
- Regulatory Hurdles: While the patent protects the formulation, any product based on it will still need to undergo rigorous regulatory review by health authorities (e.g., the European Medicines Agency, national agencies) to demonstrate safety, efficacy, and bioequivalence if it is to replace existing LMWH therapies.
- Market Size and Growth: The global anticoagulation market is substantial, driven by the increasing prevalence of cardiovascular diseases and thrombotic disorders. Stable, more convenient LMWH formulations could capture a significant share of this market.
- Investment and R&D Focus: The patent signals Rovi's strategic focus on LMWH formulation innovation, potentially attracting investment and partnerships in this specific area of drug development.
The commercial value of ES2861374 is directly tied to the ability to translate the patented technology into a marketable product that offers tangible benefits over existing LMWH treatments.
How Does ES2861374 Interact with Existing LMWH Patents?
ES2861374 interacts with existing LMWH patents primarily by focusing on formulation rather than the active pharmaceutical ingredient (API) itself. This distinction is critical for patent law and commercial strategy.
Interaction dynamics:
- Complementary, Not Conflicting: The primary patents covering the synthesis and composition of specific LMWHs (e.g., enoxaparin, dalteparin) have largely expired or are nearing expiry. ES2861374 does not challenge these foundational patents. Instead, it builds upon the availability of LMWH as a known therapeutic agent.
- Post-Patent Expiry Strategy: This type of patent filing is a common strategy for pharmaceutical companies to extend market exclusivity and create new commercial opportunities after the expiry of core API patents. By patenting a novel formulation, a company can secure a new period of protection for a product based on a well-established, albeit off-patent, drug.
- Freedom to Operate (FTO) Considerations: For generic manufacturers seeking to produce LMWH, ES2861374 necessitates careful FTO analysis. While they may be free to manufacture the LMWH API itself, they would need to ensure that their final dosage form does not infringe upon the specific claims of ES2861374. This means avoiding the specific combination of LMWH with the claimed stabilizing and disintegrant agents in a solid, low-moisture composition.
- Infringement Risk: Any company attempting to develop and market a stable solid LMWH formulation that utilizes the claimed excipients and low-moisture characteristics would be at risk of infringing ES2861374. The precise wording of the claims will dictate the boundaries of infringement.
- Potential for Cross-Licensing: In some scenarios, companies might engage in cross-licensing agreements. If a generic company has a patent on a different aspect of LMWH formulation or delivery, and Rovi holds patents on stable solid forms, they might negotiate agreements to leverage each other's technologies.
- Innovation in Delivery: ES2861374 represents a significant step in LMWH delivery innovation. It addresses the limitations of current injectable formulations by aiming for improved stability and potential for less complex administration methods, thereby creating a new layer of patent protection in the LMWH field.
In essence, ES2861374 operates in the space after the initial compound patents have matured, focusing on the technological advancements that enhance the utility and marketability of an established drug class.
Key Takeaways
- Patent ES2861374 by Laboratorios Farmacéuticos Rovi S.A. protects novel solid pharmaceutical formulations of low molecular weight heparin (LMWH).
- The core innovation lies in enhancing LMWH stability in solid form through specific combinations of stabilizing agents (e.g., disaccharides) and disintegrants, in a low-moisture composition.
- The patent claims are specific to these formulated solid compositions and methods of preparation, not the LMWH molecule itself.
- The patent landscape for LMWH is characterized by expired originator patents for the API, leading to increased generic competition and a shift in innovation towards advanced formulations and delivery systems.
- ES2861374 aims to provide commercial advantages through extended market exclusivity, differentiation from injectable LMWH, reduced storage/distribution costs, and potentially improved patient convenience.
- The patent's interaction with existing LMWH patents is complementary, focusing on formulation advancements post-API patent expiry, and requires careful Freedom to Operate analysis for generic manufacturers.
Frequently Asked Questions
What types of LMWH are covered by ES2861374?
The patent covers "low molecular weight heparin" generally, with specific claims mentioning unfractionated heparin and LMWH derived from it.
Can a company still sell LMWH injectables if this patent is in force?
Yes, provided their injectable formulations do not infringe any active patents covering those specific injectable forms. ES2861374 pertains to stable solid formulations.
What are the implications of the "low moisture" requirement in the claims?
This requirement is critical for preventing degradation of LMWH, which is sensitive to hydrolysis. It defines a key characteristic of the stable solid form.
Does ES2861374 enable oral administration of LMWH?
The patent itself claims solid formulations. While improved stability is a prerequisite for developing alternative delivery routes, the patent does not directly claim oral administration of LMWH.
Who are the main competitors in the LMWH market that might be affected by this patent?
Major LMWH players include Sanofi (with enoxaparin products), Pfizer/BMS (with dalteparin), and numerous generic manufacturers of enoxaparin, dalteparin, and tinzaparin.
What is the typical duration of patent protection for a formulation like ES2861374?
Spanish patents, under European patent law, typically have a term of 20 years from the filing date, subject to annual renewal fees.
Citations
[1] Laboratorios Farmacéuticos Rovi S.A. (2023). ES2861374 T3: Solid pharmaceutical compositions comprising low molecular weight heparin. Oficina Española de Patentes y Marcas.
